Deal Library / Pharma BD Deal Intelligence

Pharma Deals of 2014

The Pharma Closeout tracks 54 deals, $479.0B in disclosed deal value, 40 with a post-close Outcome Score for the year 2014.

Median Critic Score: 75  ·  Median Outcome Score: 44

Best outcome: Novartis AG / GlaxoSmithKline plc (81)  ·  Weakest outcome: Akorn, Inc. / VPI Holdings Corp. (VersaPharm Incorporated) (14)

All 54 deals

• Novartis AG / GlaxoSmithKline plc — 2014 · $16.0B · Worked — the deal delivered on its rationale.
• Merck KGaA / Sigma-Aldrich Corporation — 2014 · $17.0B · Worked — the deal delivered on its rationale.
• Roche Holding AG / IQuum, Inc. — 2014 · $450M · Worked — the deal delivered on its rationale.
• Pfizer Inc. / Baxter International Inc. (commercial vaccines portfolio) — 2014 · $635M · Worked — the deal delivered on its rationale.
• GSK plc / Novartis AG — 2014 · $16.0B · Worked — the deal delivered on its rationale.
• Actavis plc / Forest Laboratories — 2014 · $25.0B · Worked — the deal delivered on its rationale.
• Roche Holding AG / Genia Technologies, Inc. — 2014 · $350M · Largely worked — most objectives met.
• Bayer AG / Merck Consumer Health — 2014 · $14.2B · Largely worked — most objectives met.
• Eli Lilly and Company / Novartis Animal Health — 2014 · $5.4B · Largely worked — most objectives met.
• Sun Pharmaceutical Industries Ltd. / Ranbaxy Laboratories Limited — 2014 · $4.0B · Largely worked — most objectives met.
• Medtronic plc / Covidien plc — 2014 · $42.9B · Largely worked — most objectives met.
• Zimmer Holdings Inc. / Biomet Inc. — 2014 · $13.3B · Largely worked — most objectives met.
• Actavis plc / Allergan, Inc. — 2014 · $70.5B · Largely worked — most objectives met.
• Bayer AG / Merck & Co. Inc. — 2014 · $14.2B · Mixed — partial payoff, real shortfalls.
• Pfizer Inc. / Merck KGaA — 2014 · $2.9B · Mixed — partial payoff, real shortfalls.
• Roche Holding AG / InterMune Inc. — 2014 · $8.3B · Mixed — partial payoff, real shortfalls.
• Roche Holding AG / Seragon Pharmaceuticals, Inc. — 2014 · $1.7B · Mixed — partial payoff, real shortfalls.
• Mallinckrodt plc / Cadence Pharmaceuticals, Inc. — 2014 · $1.4B · Mixed — partial payoff, real shortfalls.
• Endo International plc / Auxilium Pharmaceuticals, Inc. — 2014 · $2.6B · Mixed — partial payoff, real shortfalls.
• AstraZeneca PLC / Definiens AG — 2014 · $150M · Mixed — partial payoff, real shortfalls.
• Otsuka Pharmaceutical Co., Ltd. / Avanir Pharmaceuticals, Inc. — 2014 · $3.5B · Underwhelmed — fell short of the thesis.
• Merck & Co. Inc. / Cubist Pharmaceuticals — 2014 · $9.5B · Underwhelmed — fell short of the thesis.
• Sanofi SA / Alnylam Pharmaceuticals, Inc. — 2014 · $700M · Underwhelmed — fell short of the thesis.
• Pfizer Inc. / InnoPharma, Inc. — 2014 · $360M · Underwhelmed — fell short of the thesis.
• Mylan Inc. / Abbott Laboratories (non-U.S. developed-markets specialty and branded generics business) — 2014 · $5.3B · Underwhelmed — fell short of the thesis.
• AstraZeneca PLC / Almirall S.A. (respiratory franchise) — 2014 · $2.1B · Underwhelmed — fell short of the thesis.
• AbbVie Inc. / Shire plc — 2014 · $54.0B · Underwhelmed — fell short of the thesis.
• Pfizer Inc. / AstraZeneca PLC — 2014 · $118.0B · Did not work — the deal failed to deliver.
• Roche Holding AG / Santaris Pharma A/S — 2014 · $450M · Did not work — the deal failed to deliver.
• Novartis AG / CoStim Pharmaceuticals, Inc. — 2014 · Did not work — the deal failed to deliver.
• Forest Laboratories, Inc. / Aptalis Pharma Inc. — 2014 · $2.9B · Did not work — the deal failed to deliver.
• Endo International plc / DAVA Pharmaceuticals, Inc. — 2014 · $600M · Did not work — the deal failed to deliver.
• Valeant Pharmaceuticals International, Inc. / PreCision Dermatology, Inc. — 2014 · $475M · Did not work — the deal failed to deliver.
• Bristol-Myers Squibb Company / Five Prime Therapeutics, Inc. — 2014 · Did not work — the deal failed to deliver.
• Shire plc / Lumena Pharmaceuticals, Inc. — 2014 · $260M · Did not work — the deal failed to deliver.
• Endo Health Solutions Inc. / Boca Pharmacal, LLC — 2014 · $225M · Did not work — the deal failed to deliver.
• Mallinckrodt plc / Questcor Pharmaceuticals, Inc. — 2014 · $5.6B · Did not work — the deal failed to deliver.
• Endo International plc / Grupo Farmaceutico Somar SAPI de CV — 2014 · $270M · Did not work — the deal failed to deliver.
• Merck & Co. Inc. / Idenix Pharmaceuticals — 2014 · $3.9B · Did not work — the deal failed to deliver.
• Akorn, Inc. / VPI Holdings Corp. (VersaPharm Incorporated) — 2014 · $440M · Did not work — the deal failed to deliver.
• Bristol-Myers Squibb Company / Ono Pharmaceutical Co., Ltd. — 2014
• Eli Lilly and Company / Immunocore Limited — 2014 · $365M
• Celgene Corporation / Sutro Biopharma, Inc. — 2014 · $185M
• AbbVie Inc. / Infinity Pharmaceuticals, Inc. — 2014 · $805M
• Eli Lilly and Company / Adocia SA — 2014 · $570M
• GlaxoSmithKline plc / Adaptimmune Therapeutics plc — 2014 · $350M
• Pfizer Inc. / Cellectis SA — 2014 · $2.9B
• AbbVie Inc. / Calico LLC — 2014 · $1.5B
• Sanofi SA / MannKind Corporation — 2014 · $925M
• Celgene Corporation / Forma Therapeutics Holdings, LLC — 2014 · $600M
• Merck & Co. Inc. / Ablynx NV — 2014 · $2.3B
• Bristol-Myers Squibb Company / CytomX Therapeutics, Inc. — 2014 · $1.2B
• Servier SAS / Cellectis SA — 2014 · $850M
• Auxilium Pharmaceuticals, Inc. / QLT Inc. — 2014 · $850M

← Deal Library  ·  Interactive search  ·  How we score deals